Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 4:39 PM
Ignite Modification Date:
2025-12-24 @ 4:39 PM
NCT ID:
NCT07173166
Brief Summary:
The goal of this clinical trial is to learn if two non-pharmacological strategies can help reduce neurotoxicity caused by CAR-T cell therapy in adult patients with hematologic cancer, both sexes, aged 18 to 80 years. The strategies are:
* A structured physical activity program.
* A combination of physical activity and nutritional recommendations.
The main questions it aims to answer are:
* Does physical activity help lower the risk or severity of neurotoxicity after CAR-T therapy?
* Does combining physical activity with nutritional recommendations provide greater protection against neurotoxicity than physical activity alone?
Researchers will compare two intervention groups with a control group (no intervention) to see which approach is most effective in reducing neurotoxicity and improving recovery.
Participants will be randomly assigned to one of three groups using stratified randomization to ensure balanced clinical and demographic characteristics:
* Group A: Structured physical activity program.
* Group B: Structured physical activity program combined wuth nutritional recommendations.
* Group C: No intervention; used to establish baseline patterns.
Participants will be evaluated periodically by study professionals. Comprehensive records of symptoms, health measurements, and relevant lifestyle data will be maintained throughout the study.
Detailed Description:
A parallel-group, multicenter and randomized controlled clinical trial will be conducted from July 2025 to July 2027. The study will evaluate the effectiveness of two non-pharmacological interventions in reducing neurotoxicity associated with CAR-T cell therapy in adult patients with hematologic cancer.
A total of 100 patients will be enrolled and randomly assigned into three groups using stratified randomization performed by an individual external to the research team.
The intervention will begin at least one month prior to CAR-T cell infusion. Participants will be followed weekly before, during, and for four weeks after therapy. Interventions and evaluations will be carried out in the same hospital where the patient receives treatment, and always by the same multidisciplinary team (hematologists, nurses, nutritionists, physiotherapists).
Primary and secondary outcomes will be assessed at baseline (prior to intervention), during treatment, and post-treatment follow-up. Written informed consent will be obtained from all participants before enrollment.
Study:
NCT07173166
Study Brief:
Protocol Section:
NCT07173166